Skip to main content
Smart Investors Daily
MD

NASDAQ · MDXH

MDxHealth SA Ordinary Shares

Healthcare · Medical - Diagnostics & Research

$0.18

Down-$0.03 (-14.34%)

Updated Oct 23, 2026, 7:15 AM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
168.79M
P/E ratio
-5.04
Dividend yield
0.00%
52-week range
$0.17 – $3.56
Volume
2.97M
Avg. volume
210.84K

Price performance · MDXH

MDXH price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 22, 2026

MDXH closed at $0.18 after 21 trading sessions, down 68.38% for the selected period.

Last close
$0.18
Period change
-68.38%
Period low
$0.18
Period high
$0.66
Daily close
View OHLC price history
MDXH OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 22, 2026$0.217$0.217$0.1755$0.1842.97M
Oct 21, 2026$0.18$0.22$0.18$0.21482.94M
Oct 20, 2026$0.185$0.1974$0.1753$0.19442.65M
Oct 19, 2026$0.21$0.2103$0.171$0.18323.93M
Oct 16, 2026$0.40$0.41$0.1863$0.206617.31M
Oct 15, 2026$0.64$0.6499$0.576$0.6036791.5K
Oct 14, 2026$0.6657$0.682$0.63$0.6317211.67K
Oct 13, 2026$0.602$0.67$0.602$0.66488.54K
Oct 12, 2026$0.58$0.6119$0.58$0.6039294.05K
Oct 9, 2026$0.5754$0.5964$0.5712$0.589748.14K
Oct 8, 2026$0.60$0.6061$0.5752$0.580560.9K
Oct 7, 2026$0.5939$0.6047$0.59$0.5998333.2K
Oct 6, 2026$0.61$0.6102$0.5873$0.5999184.52K
Oct 5, 2026$0.5681$0.61$0.5603$0.5969126.2K
Oct 2, 2026$0.57$0.60$0.56$0.57179.34K
Oct 1, 2026$0.60$0.60$0.5596$0.5762117.81K
Sep 30, 2026$0.5201$0.6398$0.5201$0.5846451.79K
Sep 29, 2026$0.5316$0.5499$0.5185$0.52311.05K
Sep 28, 2026$0.56$0.5742$0.546$0.54895.1K
Sep 25, 2026$0.58$0.5999$0.5604$0.5652236.25K
Sep 24, 2026$0.6046$0.6046$0.5628$0.582222.72K

Latest MDXH news

The latest Smart Investors Daily articles mentioning MDXH.

MDXH research

Overview

Company profile and research snapshot.

Company profile

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$15.00
Implied upside
—
Analysts
—
MDXH recent ratings
DateFirmRatingTarget
Oct 19, 2026BTIGNeutral—
Aug 21, 2026BTIGBuy—
Aug 14, 2026Lake StreetBuy—
May 14, 2026Lake StreetBuy—
May 14, 2026TD CowenBuy—
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.